All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2023; the latest 2025-04-29.
From the record
Zhengye Biotechnology Holding Limited's filings since 2023 show 1 warning event: a late-report notice (Form NT 10-K or NT 10-Q, the latest 2025-04-29) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-23.5% a year over 4 filed years; profitable in 3 of 4.
From the record
Zhengye Biotechnology Holding Limited's 4 filed years say what it did: revenue went from CNY 260 million in fiscal 2022 to CNY 116 million in fiscal 2025, down 23.5% a year; it rose in 0 of 3 years; the deepest fall was 55% from fiscal 2022 to fiscal 2025; net income was positive in 3 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 1.2% a year. 54% of cash flow returned. Insiders: 0 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, Zhengye Biotechnology Holding Limited's diluted share count grew about 1.2% a year, and dividends and buybacks returned about 54% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE -23%: lost 23¢ per shareholder dollar. Leverage 30%: owes 30¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Zhengye Biotechnology Holding Limited lost about 23 cents for every dollar of shareholders' money, and gross profitability: its products earned about 5 cents per dollar of everything the company owns. Leverage: it owed about 30 cents per dollar of assets, and net share issuance: its share count grew 3.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 39% of 315 in its family; net margin -60%.
From the record
Zhengye Biotechnology Holding Limited's standing among 315 graded names in its industry family: revenue of CNY 116 million in fiscal 2025 is not ranked by size, since the family reports in another currency; a net margin of -60% ranks in the top 42%; revenue growth of -23.5% a year over the last 3 filed years ranks in the bottom 19% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 5.0/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Zhengye Biotechnology Holding Limited's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 34% of 273 in its family for room to expand.
From the record
Zhengye Biotechnology Holding Limited's room to grow, from the newest filed statements (fiscal 2025): cash of CNY 50 million against debt of CNY 10 million leaves 9.3% of its assets as net cash, bottom 24% of its family; cash from operations less capital spending is 10.6% of revenue (top 20%); a gross margin of 20.5% (bottom 11%); research spending of 15.5% of revenue (bottom 19%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 38% of 306 in its family for growth drivers.
From the record
Zhengye Biotechnology Holding Limited's growth drivers, from the filed years to fiscal 2025: revenue grew -23.5% a year over the last three filed years against -23.5% over all 4, speeding up (top 40% of its family); the newest year grew -37.6% (bottom 21%); research spending grew 10.3% a year (top 38%); capital spending grew -66.7% a year (bottom 9%) (its annual reports). Zhengye Biotechnology Holding Limited tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 18% of 233 in its family for expectations against reality.
From the record
Zhengye Biotechnology Holding Limited's newest year against its own record: revenue of CNY 116 million in fiscal 2025 came in 26.2% below the CNY 158 million its prior three years' pace pointed to (bottom 29% of its family); net income of CNY 70 million against a prior three-year average of CNY 30 million (bottom 6%); a net margin of -60% against 13% before (bottom 21%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made